Nevertheless, ILD continues to take some of the shine off the efficacy results generated with Daiichi Sankyo's ADC candidates. HER3 is expressed in more than 80% of EGFR-mutant NSCLC, and ...
Breast cancer data Now, Daiichi Sankyo has been able to show signs of efficacy for the ADC beyond lung cancer, with the first data from a phase 1/2 study in patients with HER3-positive metastatic ...
As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...
Hosted on MSN2mon
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5mUnder that agreement, Daiichi Sankyo gained exclusive global rights to develop and commercialise gatipotuzumab as an antibody-drug conjugate (ADC ... ADCs targeting HER3, B7-H3, and CDH6.
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer ...
Hosted on MSN1mon
Adcendo raises $135m as ADC funding frenzy continuesIn October 2023, MSD and Daiichi Sankyo entered into a deal worth up to $22bn to develop and commercialise three ADC candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (DLK-DXd ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback